Managed Healthcare Executive: Prime Therapeutics Finds No Medical Cost Offsets for GLP-1 Obesity Drugs | AMCP Annual 2025 - Prime Therapeutics
In the News
Managed Healthcare Executive: Prime Therapeutics Finds No Medical Cost Offsets for GLP-1 Obesity Drugs | AMCP Annual 2025
Managed Healthcare Executive: A Prime Therapeutics analysis of real-world data has found that medical costs for patients taking GLP-1 drugs for obesity had increased by about $1,338 per member, compared with a matched control group

About Prime Therapeutics

Prime Therapeutics LLC (Prime) is a diversified pharmacy solutions organization. We offer innovative pharmacy benefit management, specialty and medical drug management, and state government solutions to millions of people across the country. At Prime, we’re reimagining pharmacy solutions to provide the care we’d want for our loved ones. We challenge the way it’s always been done to develop intelligently designed solutions that deliver savings, simplicity and support to help people achieve better health. For more information, visit us at PrimeTherapeutics.com or follow us on LinkedIn.